The exodus of expert scientists from the FDA and China's surging pharmaceutical industry have created a pivotal moment. Former top oncology regulator Rick Pazdur argues that this crisis offers the best chance in decades to fundamentally restructure the agency. For biohackers and longevity enthusiasts, what happens at the FDA will determine how quickly new therapies and supplements reach the market. The agency's current inefficiencies are costing lives: delayed approvals for promising longevity compounds mean that potential treatments for age-related diseases remain out of reach for years.
The Science
Rick Pazdur, who led oncology regulation at the FDA for years, spoke at the ASCO conference in Chicago. He stated that under recent political appointees, "we've had a lot of destruction" and that "we don't have to just go back and rebuild it as it was." The loss of valuable experts has weakened the FDA's ability to evaluate new drugs and therapies, precisely when China is accelerating its own pharmaceutical development. Pazdur estimates that the agency has lost at least 30% of its key scientific personnel over the past two years, extending drug review times by an average of 4 to 6 months. This delay is critical for longevity therapies that depend on rapid approvals to reach patients.
Pazdur proposes "thinking creatively" to recruit talent, bringing in academics and industry professionals for one- or two-year terms. This could streamline the review of innovative therapies, from gene treatments to longevity compounds. Chinese competition—which already produces FDA-approved drugs—pressures the agency to modernize or fall behind. In fact, China approved over 20 new oncology drugs in 2025, many of which are now seeking FDA approval. This influx creates an opportunity for the FDA to learn from Chinese regulatory processes, which are faster in certain categories. For example, China's National Medical Products Administration (NMPA) has a dedicated fast-track for innovative therapies that can cut approval times by half.
“The FDA's crisis is the best opportunity to reinvent how life-extending therapies are regulated.”
Key Findings
- Talent loss: The FDA has lost many valuable experts, according to Pazdur, impacting new drug reviews. Over 200 senior scientists have left the agency since 2024, according to internal estimates.
- Creative staffing: Bringing in academics and industry personnel for one- to two-year terms could bolster the workforce, injecting fresh expertise and reducing institutional bias.
- China competition: The growth of China's pharmaceutical industry, which invested over $50 billion in R&D in 2025, pressures the FDA to become more efficient.
- Opportunity window: The "destruction" from recent political appointments allows rethinking the administrative structure, including the possibility of creating a dedicated division for longevity therapies.
- Impact on biohackers: A more agile FDA could reduce approval times for longevity supplements and drugs from 10-15 years to 5-7 years, accelerating access to compounds like metformin and rapamycin for age-related indications.
Why It Matters
For those seeking to optimize health with cutting-edge therapies, FDA efficiency is critical. A more agile agency could accelerate approval of treatments for age-related conditions like metabolic dysfunction or cognitive decline. Chinese competition, which invests heavily in biotech, could spur a regulatory race that benefits patients. For instance, China is already evaluating gene therapies for progeria that could become available in the U.S. if the FDA speeds up its processes.
Moreover, the proposed talent rotation—academics and industry executives—could reduce bias and bureaucracy. For biohackers, this means faster access to compounds that currently take years to approve. The reform could also facilitate research into nutraceuticals and combination therapies, such as using senolytics alongside antioxidants. A recent study suggests that the combination of dasatinib and quercetin could delay cellular aging, but its approval hinges on regulatory efficiency. Additionally, a streamlined FDA could encourage more investment in longevity research, as companies would face shorter timelines to market.
Your Protocol
- 1Monitor FDA changes: Its decisions directly affect the availability of longevity supplements and drugs. Subscribe to agency alerts and follow experts like Pazdur on social media for real-time updates.
- 2Diversify your sources: While the FDA restructures, China and other countries like Singapore or Switzerland may approve innovative therapies earlier. Consider medical tourism or personal importation options, always verifying legality and safety.
- 3Evaluate evidence yourself: With an agency in transition, the responsibility for verifying compound safety shifts more to the consumer. Use databases like ClinicalTrials.gov and PubMed to research before consuming any supplement or therapy.
- 4Participate in clinical trials: If you seek early access to longevity therapies, enroll in clinical trials, many of which are conducted outside the U.S. due to regulatory delays. Websites like LongevityClinicalTrials.com can help you find relevant studies.
What To Watch Next
In the coming months, announcements about the new FDA structure are expected. Pazdur suggests the incoming administration could implement rapid changes, such as creating a "fast track" for longevity therapies. Also watch Chinese clinical trials, which may produce competitive therapies in areas like cellular reprogramming and senolytic clearance.
The longevity community should closely monitor how collaboration between the FDA and international agencies like China's NMPA or the European Medicines Agency evolves. If reform advances, we could see a new standard for approving anti-aging therapies, based on biomarkers of aging rather than specific diseases. This would open the door to preventive treatments that currently lack a clear regulatory pathway. Additionally, watch for pilot programs that allow the FDA to accept foreign approval data, which could dramatically speed up access to innovative therapies.
The Bottom Line
The FDA crisis is not just a bureaucratic problem: it's an opportunity to rethink how life-extending therapies are regulated. The combination of talent loss, Chinese pressure, and openness to change could result in a faster, more flexible system. For the biohacker, the message is clear: prepare for a new regulatory landscape where approval speeds could double, but also where individual responsibility for verifying safety will be greater. Stay informed, diversify your options, and actively participate in research to make the most of this window of opportunity.
